Physician profile
Mark G Borek
NPI 1922012707
$10,799.67
in general payments reported to CMS, 2019-2025
41 companies · $936 in 2025
The $936 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,788 · 2020: $1,878 · 2021: $1,836 · 2022: $1,289 · 2023: $1,528 · 2024: $1,546 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,009.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,259.01 | 2019-2025 | Cardiomems, Mitraclip, Jot Dx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,027.20 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $892.54 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $807.79 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $783.92 | 2019-2022 | |
| Pfizer INC. | $748.70 | 2019-2025 | |
| Amgen INC. | $745.32 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $723.55 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $692.56 | 2021-2025 | Verquvo, Winrevair |
| Sanofi-Aventis U.S. LLC | $555.43 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $398.17 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Esperion Therapeutics, INC. | $271.75 | 2020-2025 | Nexletol |
| Daiichi Sankyo INC. | $246.03 | 2023-2024 | Injectafer |
| Novo Nordisk INC | $141.78 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Chiesi USA, INC. | $134.15 | 2019-2023 | Kengreal, Cleviprex |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $129.83 | 2025 | |
| Edwards Lifesciences Corporation | $111.31 | 2021-2025 | Sapien 3 Ultra Resilia |
| Lundbeck LLC | $98.71 | 2019-2020 | |
| Astellas Pharma US INC | $93.80 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $86.35 | 2020-2021 | |
| Medtronic, INC. | $84.42 | 2023 | Linq II |
| Kiniksa Pharmaceuticals International, Plc | $81.72 | 2024 | Arcalyst |
| Medicomp INC | $72.29 | 2023 | Telepatch Cardiac Monitor |
| Alnylam Pharmaceuticals INC. | $71.66 | 2019-2024 | Amvuttra |
| Irhythm Technologies, INC. | $49.18 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Regeneron Healthcare Solutions, INC. | $49.04 | 2019-2021 | |
| Inspire Medical Systems, INC. | $47.05 | 2023-2024 | Inspire |
| Glaxosmithkline, LLC. | $45.31 | 2025 | Shingrix, Arexvy |
| Philips North America LLC | $39.48 | 2024 | (Cm9) Amb Mon & Diag Und, (5091) Amb Mon & Diag Und |
| Arbor Pharmaceuticals, INC. | $38.98 | 2021 | |
| Kestra Medical Technology Services, INC. | $38.26 | 2023 | Assure Wcd |
| Boston Scientific Corporation | $37.18 | 2020-2024 | Watchman Flx |
| Recor Medical INC | $31.10 | 2025 | Paradise Ultrasound Renal Denervation System |
| Bardy Diagnostics, INC. | $25.57 | 2022 | |
| Gilead Sciences, INC. | $23.79 | 2019 | |
| Cmp Pharma, INC. | $22.73 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $20.63 | 2024 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.61 | 2020 | |
| Bridgebio Pharma, INC. | $19.54 | 2025 | Attruby |
| Shield Therapeutics INC | $18.76 | 2025 | |
| Heartflow, INC. | $15.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Borek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.